메뉴 건너뛰기




Volumn 23, Issue 15, 2017, Pages 4270-4279

PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

EID: 85027190177     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-3146     Document Type: Article
Times cited : (115)

References (41)
  • 3
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517–26.
    • (2011) N Engl J Med , vol.364 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3    O'Day, S.4    Weber, J.5    Garbe, C.6
  • 4
    • 84879759020 scopus 로고    scopus 로고
    • Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
    • Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134–44.
    • (2013) N Engl J Med , vol.369 , pp. 134-144
    • Hamid, O.1    Robert, C.2    Daud, A.3    Hodi, F.S.4    Hwu, W.J.5    Kefford, R.6
  • 6
    • 84931083080 scopus 로고    scopus 로고
    • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A rando-mised, controlled, open-label, phase 3 trial
    • Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a rando-mised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16: 375–84.
    • (2015) Lancet Oncol , vol.16 , pp. 375-384
    • Weber, J.S.1    D'Angelo, S.P.2    Minor, D.3    Hodi, F.S.4    Gutzmer, R.5    Neyns, B.6
  • 8
    • 84959577118 scopus 로고    scopus 로고
    • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
    • Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–20.
    • (2016) Lancet , vol.387 , pp. 1909-1920
    • Rosenberg, J.E.1    Hoffman-Censits, J.2    Powles, T.3    Van Der Heijden, M.S.4    Balar, A.V.5    Necchi, A.6
  • 9
    • 84973295081 scopus 로고    scopus 로고
    • Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation
    • Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M, et al. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51:850–2.
    • (2016) Bone Marrow Transplant , vol.51 , pp. 850-852
    • Yared, J.A.1    Hardy, N.2    Singh, Z.3    Hajj, S.4    Badros, A.Z.5    Kocoglu, M.6
  • 10
    • 84944937210 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
    • Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627–39.
    • (2015) N Engl J Med , vol.373 , pp. 1627-1639
    • Borghaei, H.1    Paz-Ares, L.2    Horn, L.3    Spigel, D.R.4    Steins, M.5    Ready, N.E.6
  • 15
    • 80053648839 scopus 로고    scopus 로고
    • Integrated NY-ESO-1 antibody and CD8þ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
    • Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, et al. Integrated NY-ESO-1 antibody and CD8þ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 2011;108:16723–8.
    • (2011) Proc Natl Acad Sci U S A , vol.108 , pp. 16723-16728
    • Yuan, J.1    Adamow, M.2    Ginsberg, B.A.3    Rasalan, T.S.4    Ritter, E.5    Gallardo, H.F.6
  • 16
    • 84970047228 scopus 로고    scopus 로고
    • Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab
    • Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 2016;22:2908–18.
    • (2016) Clin Cancer Res , vol.22 , pp. 2908-2918
    • Martens, A.1    Wistuba-Hamprecht, K.2    Geukes Foppen, M.3    Yuan, J.4    Postow, M.A.5    Wong, P.6
  • 17
    • 84936821508 scopus 로고    scopus 로고
    • Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature
    • Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W-J, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. ASCO Annual Meeting; J Clin Oncol 2015;33: suppl; abstr 3001.
    • (2015) ASCO Annual Meeting; J Clin Oncol , vol.33
    • Ribas, A.1    Robert, C.2    Hodi, F.S.3    Wolchok, J.D.4    Joshua, A.M.5    Hwu, W.-J.6
  • 18
    • 84961221351 scopus 로고    scopus 로고
    • Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
    • Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016;165:35–44.
    • (2016) Cell , vol.165 , pp. 35-44
    • Hugo, W.1    Zaretsky, J.M.2    Sun, L.3    Song, C.4    Moreno, B.H.5    Hu-Lieskovan, S.6
  • 20
    • 84956654314 scopus 로고    scopus 로고
    • Melanoma-specific MHC-II expression represents a tumour-autono-mous phenotype and predicts response to anti-PD-1/PD-L1 therapy
    • Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, et al. Melanoma-specific MHC-II expression represents a tumour-autono-mous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun 2016;7:10582.
    • (2016) Nat Commun , vol.7 , pp. 10582
    • Johnson, D.B.1    Estrada, M.V.2    Salgado, R.3    Sanchez, V.4    Doxie, D.B.5    Opalenik, S.R.6
  • 21
    • 84988700642 scopus 로고    scopus 로고
    • PD-L1 expression in human cancers and its association with clinical outcomes
    • Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 2016;9: 5023–39.
    • (2016) Onco Targets Ther , vol.9 , pp. 5023-5039
    • Wang, X.1    Teng, F.2    Kong, L.3    Yu, J.4
  • 22
    • 84969921308 scopus 로고    scopus 로고
    • Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 expression a biomarker for patient selection?
    • Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, et al. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 expression a biomarker for patient selection? Drugs 2016;76:925–45.
    • (2016) Drugs , vol.76 , pp. 925-945
    • Festino, L.1    Botti, G.2    Lorigan, P.3    Masucci, G.V.4    Hipp, J.D.5    Horak, C.E.6
  • 23
    • 84963621254 scopus 로고    scopus 로고
    • Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
    • Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016;16:275–87.
    • (2016) Nat Rev Cancer , vol.16 , pp. 275-287
    • Topalian, S.L.1    Taube, J.M.2    Anders, R.A.3    Pardoll, D.M.4
  • 26
    • 84920956735 scopus 로고    scopus 로고
    • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
    • Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563–7.
    • (2014) Nature , vol.515 , pp. 563-567
    • Herbst, R.S.1    Soria, J.C.2    Kowanetz, M.3    Fine, G.D.4    Hamid, O.5    Gordon, M.S.6
  • 27
    • 84896974949 scopus 로고    scopus 로고
    • PD-L1 expression in clear cell renal cell carcinoma: An analysis of nephrectomy and sites of metastases
    • Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, et al. PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. J Cancer 2014;5:166–72.
    • (2014) J Cancer , vol.5 , pp. 166-172
    • Jilaveanu, L.B.1    Shuch, B.2    Zito, C.R.3    Parisi, F.4    Barr, M.5    Kluger, Y.6
  • 28
    • 84944460024 scopus 로고    scopus 로고
    • Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens
    • Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L, et al. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015;6: 24990–5002.
    • (2015) Oncotarget , vol.6 , pp. 24990-25002
    • Baine, M.K.1    Turcu, G.2    Zito, C.R.3    Adeniran, A.J.4    Camp, R.L.5    Chen, L.6
  • 29
    • 84941966146 scopus 로고    scopus 로고
    • Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites
    • Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, et al. Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res 2015;21:3052–60.
    • (2015) Clin Cancer Res , vol.21 , pp. 3052-3060
    • Kluger, H.M.1    Zito, C.R.2    Barr, M.L.3    Baine, M.K.4    Chiang, V.L.5    Sznol, M.6
  • 30
    • 70349445575 scopus 로고    scopus 로고
    • C-Raf is associated with disease progression and cell proliferation in a subset of melanomas
    • Jilaveanu LB, Zito CR, Aziz SA, Conrad PJ, Schmitz JC, Sznol M, et al. C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clin Cancer Res 2009;15:5704–13.
    • (2009) Clin Cancer Res , vol.15 , pp. 5704-5713
    • Jilaveanu, L.B.1    Zito, C.R.2    Aziz, S.A.3    Conrad, P.J.4    Schmitz, J.C.5    Sznol, M.6
  • 31
    • 33745725760 scopus 로고    scopus 로고
    • Expression of tumor necrosis factor–related apoptosis-inducing ligand receptors 1 and 2 in melanoma
    • McCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, et al. Expression of tumor necrosis factor–related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res 2006;12:3856–63.
    • (2006) Clin Cancer Res , vol.12 , pp. 3856-3863
    • McCarthy, M.M.1    DiVito, K.A.2    Sznol, M.3    Kovacs, D.4    Halaban, R.5    Berger, A.J.6
  • 33
    • 0036852721 scopus 로고    scopus 로고
    • Automated subcellular localization and quantification of protein expression in tissue microarrays
    • Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323–7.
    • (2002) Nat Med , vol.8 , pp. 1323-1327
    • Camp, R.L.1    Chung, G.G.2    Rimm, D.L.3
  • 34
    • 18544380239 scopus 로고    scopus 로고
    • Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
    • Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793–800.
    • (2002) Nat Med , vol.8 , pp. 793-800
    • Dong, H.1    Strome, S.E.2    Salomao, D.R.3    Tamura, H.4    Hirano, F.5    Flies, D.B.6
  • 35
    • 84904024273 scopus 로고    scopus 로고
    • Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
    • Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064–74.
    • (2014) Clin Cancer Res , vol.20 , pp. 5064-5074
    • Taube, J.M.1    Klein, A.2    Brahmer, J.R.3    Xu, H.4    Pan, X.5    Kim, J.H.6
  • 36
    • 84961249398 scopus 로고    scopus 로고
    • PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells
    • Mahoney KM, Sun H, Liao X, Hua P, Callea M, Greenfield EA, et al. PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells. Cancer Immunol Res 2015;3:1308–15.
    • (2015) Cancer Immunol Res , vol.3 , pp. 1308-1315
    • Mahoney, K.M.1    Sun, H.2    Liao, X.3    Hua, P.4    Callea, M.5    Greenfield, E.A.6
  • 37
    • 84859128199 scopus 로고    scopus 로고
    • Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
    • Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37.
    • (2012) Sci Transl Med , vol.4 , pp. 127ra37
    • Taube, J.M.1    Anders, R.A.2    Young, G.D.3    Xu, H.4    Sharma, R.5    McMiller, T.L.6
  • 38
    • 84995890821 scopus 로고    scopus 로고
    • Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma
    • Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 2016;34:4102–9.
    • (2016) J Clin Oncol , vol.34 , pp. 4102-4109
    • Daud, A.I.1    Wolchok, J.D.2    Robert, C.3    Hwu, W.J.4    Weber, J.S.5    Ribas, A.6
  • 39
    • 0032736029 scopus 로고    scopus 로고
    • B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
    • Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365–9.
    • (1999) Nat Med , vol.5 , pp. 1365-1369
    • Dong, H.1    Zhu, G.2    Tamada, K.3    Chen, L.4
  • 40
    • 33846118474 scopus 로고    scopus 로고
    • Loss of tumor suppressor PTEN function increases B7-H1 expression and immu-noresistance in glioma
    • Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immu-noresistance in glioma. Nat Med 2007;13:84–8.
    • (2007) Nat Med , vol.13 , pp. 84-88
    • Parsa, A.T.1    Waldron, J.S.2    Panner, A.3    Crane, C.A.4    Parney, I.F.5    Barry, J.J.6
  • 41
    • 84927539299 scopus 로고    scopus 로고
    • Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-kappaB
    • Gowrishankar K, Gunatilake D, Gallagher SJ, Tiffen J, Rizos H, Hersey P. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-kappaB. PLoS One 2015;10: e0123410.
    • (2015) Plos One , vol.10 , pp. e0123410
    • Gowrishankar, K.1    Gunatilake, D.2    Gallagher, S.J.3    Tiffen, J.4    Rizos, H.5    Hersey, P.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.